US Military Dietetic Internship Consortium, U.S. Army Medical Center of Excellence, Fort Sam Houston, San Antonio, TX, 78234, USA.
Obes Surg. 2021 Apr;31(4):1618-1624. doi: 10.1007/s11695-020-05169-w. Epub 2021 Jan 29.
The disease burden of type 2 diabetes (T2D) costs the military healthcare system an estimated $1.66 billion annually. Thirty-four percent of veterans and 28% of military beneficiaries are obese, a common feature of T2D. Bariatric surgery is a viable treatment for T2D, whether if long-term remission of T2D post-bariatric surgery occurs remains unknown. The purpose of this study was to assess differences between outcomes of veterans and military beneficiaries following bariatric surgery.
A retrospective cohort study assessed retirees and beneficiaries diagnosed with T2D who had bariatric surgery between 2005 and 2015. Outcomes included T2D remission and vitamin and mineral deficiencies each year for 5 years post-op, analyzed via ANOVA.
Ninety-one patients, 46 beneficiaries and 45 retirees, were included with a mean age of 51 and 57, respectively. No significant differences between T2D remission and vitamin/mineral deficiencies 5 years post-op were found between groups. Patients with uncontrolled diabetes before surgery were less likely to achieve T2D remission for all 5 years post-op, regardless of military affiliation (p < .05).
Veterans do not have better rates of T2D remission or weight loss following bariatric surgery than other populations. Control of T2D pre-surgery is a potential clinical indicator of T2D remission success following bariatric surgery.
2 型糖尿病(T2D)给军队医疗保健系统带来的疾病负担估计每年达 16.6 亿美元。34%的退伍军人和 28%的军队受益人体重超标,这是 T2D 的一个常见特征。减重手术是 T2D 的一种可行治疗方法,但减重手术后 T2D 是否长期缓解尚不清楚。本研究旨在评估退伍军人和军队受益人体重减轻手术后结局的差异。
一项回顾性队列研究评估了 2005 年至 2015 年间接受过减重手术的被诊断患有 T2D 的退休人员和受益人的结局。结果包括 T2D 缓解和术后 5 年内每年的维生素和矿物质缺乏,通过 ANOVA 进行分析。
91 名患者,46 名受益人和 45 名退休人员,平均年龄分别为 51 岁和 57 岁。两组患者术后 5 年内 T2D 缓解和维生素/矿物质缺乏之间没有显著差异。手术前糖尿病控制不佳的患者,无论是否有军队背景,术后所有 5 年 T2D 缓解的可能性均较低(p<0.05)。
退伍军人在减重手术后 T2D 缓解或体重减轻的比例并不高于其他人群。手术前 T2D 的控制可能是减重手术后 T2D 缓解成功的潜在临床指标。